Pub Date : 2025-11-01DOI: 10.1016/j.exphem.2025.104924
Norika Liu , Atsushi Nakano
The cells that comprise the circulatory system not only share developmental origins but also mutually support each other’s differentiation during early embryogenesis. Although classical models attribute embryonic hematopoiesis in mammals to the yolk sac and aorta-gonad-mesonephros (AGM) region, we and others have identified the embryonic heart as a transient hematopoietic niche. A subset of endocardial cells in the outflow tract and atrioventricular canal undergo endothelial-to-hematopoietic transition (EHT) in an Nkx2-5-dependent manner, mirroring the tinman-regulated cardio-hematopoietic program in Drosophila. These hemogenic endocardial cells, enriched in the cushion region—the primordia of cardiac valves and septa—not only contribute to local hematopoiesis but also give rise to tissue macrophages that facilitate valve morphogenesis.
These findings challenge the traditional view of hematopoietic compartmentalization and establish a novel paradigm in which the heart itself contributes to hematopoietic development. Using lineage tracing and knockout mouse models, we further show that endocardial-derived macrophages persist into adulthood as tissue-resident macrophages, particularly within cardiac valves and vasculature. Functionally, these cells appear to modulate tissue homeostasis and suppress pathological fibrosis.
In summary, our study reveals that the embryonic heart acts as a local hematopoietic organ, supplying a distinct macrophage population that contributes to both cardiac morphogenesis and long-term homeostasis. These insights broaden our understanding of the interplay between hematopoiesis and cardiogenesis and suggest new avenues for investigating tissue-resident immune cell ontogeny.
{"title":"2011 – THE EMBRYONIC HEART AS A TRANSIENT HEMATOPOIETIC SITE FOR MACROPHAGE-MEDIATED CARDIAC REMODELING","authors":"Norika Liu , Atsushi Nakano","doi":"10.1016/j.exphem.2025.104924","DOIUrl":"10.1016/j.exphem.2025.104924","url":null,"abstract":"<div><div>The cells that comprise the circulatory system not only share developmental origins but also mutually support each other’s differentiation during early embryogenesis. Although classical models attribute embryonic hematopoiesis in mammals to the yolk sac and aorta-gonad-mesonephros (AGM) region, we and others have identified the embryonic heart as a transient hematopoietic niche. A subset of endocardial cells in the outflow tract and atrioventricular canal undergo endothelial-to-hematopoietic transition (EHT) in an Nkx2-5-dependent manner, mirroring the tinman-regulated cardio-hematopoietic program in Drosophila. These hemogenic endocardial cells, enriched in the cushion region—the primordia of cardiac valves and septa—not only contribute to local hematopoiesis but also give rise to tissue macrophages that facilitate valve morphogenesis.</div><div>These findings challenge the traditional view of hematopoietic compartmentalization and establish a novel paradigm in which the heart itself contributes to hematopoietic development. Using lineage tracing and knockout mouse models, we further show that endocardial-derived macrophages persist into adulthood as tissue-resident macrophages, particularly within cardiac valves and vasculature. Functionally, these cells appear to modulate tissue homeostasis and suppress pathological fibrosis.</div><div>In summary, our study reveals that the embryonic heart acts as a local hematopoietic organ, supplying a distinct macrophage population that contributes to both cardiac morphogenesis and long-term homeostasis. These insights broaden our understanding of the interplay between hematopoiesis and cardiogenesis and suggest new avenues for investigating tissue-resident immune cell ontogeny.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104924"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.exphem.2025.104930
Alexandra Preston , Joe Frost , Megan Teh , Mohsin Badat , Andrew Armitage , Ruggiero Norfo , Sarah Wideman , Muhammad Hanifi , Natasha White , Noemi Roy , Christian Babbs , Bart Ghesquiere , James Davies , Andrew Howden , Linda Sinclair , Jim Hughes , Mira Kassouf , Robert Beagrie , Douglas Higgs , Hal Drakesmith
α-globin’s genomic next-door neighbor, Nprl3, contains 4 of the 5 α-globin enhancers. Nprl3 negatively regulates mTORC1, a master controller of cell metabolism. Nprl3, α-globin, and the α-globin enhancers have been colocated for >500 million years. However, the function of this genomic linkage is unknown.
Using a mouse in which the Nprl3 promoter is deleted (with no effect on the α-globin enhancers), we showed that Nprl3 is required for optimal erythropoiesis in fetal liver and bone marrow. On embryonic day 13.5 (E13.5) in the fetal liver, Nprl3−/− erythroid cells failed to develop beyond the proerythroblast stage. Metabolite profiling, RNA-Seq and proteomics showed that Nprl3−/− erythroblasts have overactivated mTORC1 signaling, overcharged glycolysis, and suppressed autophagy. Competitive bone marrow-fetal liver chimeras indicated a hematopoietic-intrinsic Nprl3 requirement for erythropoiesis. To study human erythropoiesis, we induced NPRL3-knockout by RNP-editing primary CD34+ cells. Edited progenitors produced fewer enucleated erythroid cells and exhibited defective mTORC1 signaling responses to fluctuating iron, amino acid, and erythropoietin (EPO) availability. Nprl3 tunes the metabolism of developing erythroid cells to their nutritional environment.
Nprl3 expression is highly elevated in erythroid cells. We showed that this is due to the interaction between the Nprl3 promoter and α-globin enhancers. We eliminated interactions (in cis) between Nprl3 and the enhancers, while maintaining enhancer control of α-globin. Remarkably, our approach resulted in erythropoietic impairment reminiscent of the Nprl3−/− genotype (with E13.5 erythroid development inhibited at the same stage of differentiation). Therefore, the ancient transcriptional hub of Nprl3, α-globin, and their enhancers supports the erythroid-specific upregulation of Nprl3 and coordinates metabolic control with red blood cell development.
{"title":"2017 – ANCIENT GENOMIC LINKAGE OF NPRL3 AND Α-GLOBIN COUPLES METABOLISM WITH ERYTHROID DEVELOPMENT","authors":"Alexandra Preston , Joe Frost , Megan Teh , Mohsin Badat , Andrew Armitage , Ruggiero Norfo , Sarah Wideman , Muhammad Hanifi , Natasha White , Noemi Roy , Christian Babbs , Bart Ghesquiere , James Davies , Andrew Howden , Linda Sinclair , Jim Hughes , Mira Kassouf , Robert Beagrie , Douglas Higgs , Hal Drakesmith","doi":"10.1016/j.exphem.2025.104930","DOIUrl":"10.1016/j.exphem.2025.104930","url":null,"abstract":"<div><div>α-globin’s genomic next-door neighbor, Nprl3, contains 4 of the 5 α-globin enhancers. Nprl3 negatively regulates mTORC1, a master controller of cell metabolism. Nprl3, α-globin, and the α-globin enhancers have been colocated for >500 million years. However, the function of this genomic linkage is unknown.</div><div>Using a mouse in which the Nprl3 promoter is deleted (with no effect on the α-globin enhancers), we showed that Nprl3 is required for optimal erythropoiesis in fetal liver and bone marrow. On embryonic day 13.5 (E13.5) in the fetal liver, Nprl3−/− erythroid cells failed to develop beyond the proerythroblast stage. Metabolite profiling, RNA-Seq and proteomics showed that Nprl3−/− erythroblasts have overactivated mTORC1 signaling, overcharged glycolysis, and suppressed autophagy. Competitive bone marrow-fetal liver chimeras indicated a hematopoietic-intrinsic Nprl3 requirement for erythropoiesis. To study human erythropoiesis, we induced NPRL3-knockout by RNP-editing primary CD34+ cells. Edited progenitors produced fewer enucleated erythroid cells and exhibited defective mTORC1 signaling responses to fluctuating iron, amino acid, and erythropoietin (EPO) availability. Nprl3 tunes the metabolism of developing erythroid cells to their nutritional environment.</div><div>Nprl3 expression is highly elevated in erythroid cells. We showed that this is due to the interaction between the Nprl3 promoter and α-globin enhancers. We eliminated interactions (in cis) between Nprl3 and the enhancers, while maintaining enhancer control of α-globin. Remarkably, our approach resulted in erythropoietic impairment reminiscent of the Nprl3−/− genotype (with E13.5 erythroid development inhibited at the same stage of differentiation). Therefore, the ancient transcriptional hub of Nprl3, α-globin, and their enhancers supports the erythroid-specific upregulation of Nprl3 and coordinates metabolic control with red blood cell development.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104930"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.exphem.2025.104928
Lev Kats , Emily Gruber , Sree Kumar , Rheana Franich , Omer Gilan , Tiffany Khong , Andrew Spencer
Multiple myeloma (MM) is a common plasma cell malignancy that remains mostly incurable. We analyzed the Cancer Gene Dependency Map and identified menin as a therapeutically actionable MM vulnerability. Gene knockout and menin inhibitor (iMenin) therapy experiments across an extensive panel of MM cell lines confirmed that ∼20% are highly sensitive to menin disruption, with an additional ∼40% demonstrating a partial response. Similar findings were also made in a separate custom panel of early passage MM lines that more closely recapitulate genetic alterations found in patients with MM.
Gene expression and chromatin profiling studies in iMenin-sensitive, intermediate, and refractory MM lines identified the master myeloma cell identity factor IRF4 as the major downstream target of menin inhibition. iMenin-sensitive lines are characterized by abundant deposition of the menin/MLL1 complex at the super-enhancer of IRF4, with iMenin treatment resulting in eviction of menin/MLL1 from chromatin and concomitant suppression of IRF4 and its target genes. Interestingly, iMenin sensitivity in MM also correlates with transcriptional signatures of immature B cells that are, in turn, inversely correlated with response to many current treatments, especially those that target the B-cell maturation antigen (BCMA).
In parallel, we also applied genome-wide CRISPR screening, which implicated the CREBBP/EP300/NCOR1 axis as a key modulator of iMenin sensitivity. Notably, clinical-grade menin and EP300 inhibitors demonstrated synergistic activity against primary patients with MM samples cultured ex vivo and against the syngeneic Vk*MYC MM model in vivo. Molecular analysis revealed deep and synergistic suppression of IRF4 potentiated by the combination. Altogether, our comprehensive study identified menin as a promising target in MM and charts potential paths for rapid clinical translation.
{"title":"2015 – MENIN ORCHESTRATES EXPRESSION OF THE MASTER PLASMA CELL TRANSCRIPTION FACTOR IRF4 AND IS AN ACTIONABLE TARGET IN MULTIPLE MYELOMA.","authors":"Lev Kats , Emily Gruber , Sree Kumar , Rheana Franich , Omer Gilan , Tiffany Khong , Andrew Spencer","doi":"10.1016/j.exphem.2025.104928","DOIUrl":"10.1016/j.exphem.2025.104928","url":null,"abstract":"<div><div>Multiple myeloma (MM) is a common plasma cell malignancy that remains mostly incurable. We analyzed the Cancer Gene Dependency Map and identified menin as a therapeutically actionable MM vulnerability. Gene knockout and menin inhibitor (iMenin) therapy experiments across an extensive panel of MM cell lines confirmed that ∼20% are highly sensitive to menin disruption, with an additional ∼40% demonstrating a partial response. Similar findings were also made in a separate custom panel of early passage MM lines that more closely recapitulate genetic alterations found in patients with MM.</div><div>Gene expression and chromatin profiling studies in iMenin-sensitive, intermediate, and refractory MM lines identified the master myeloma cell identity factor IRF4 as the major downstream target of menin inhibition. iMenin-sensitive lines are characterized by abundant deposition of the menin/MLL1 complex at the super-enhancer of IRF4, with iMenin treatment resulting in eviction of menin/MLL1 from chromatin and concomitant suppression of IRF4 and its target genes. Interestingly, iMenin sensitivity in MM also correlates with transcriptional signatures of immature B cells that are, in turn, inversely correlated with response to many current treatments, especially those that target the B-cell maturation antigen (BCMA).</div><div>In parallel, we also applied genome-wide CRISPR screening, which implicated the CREBBP/EP300/NCOR1 axis as a key modulator of iMenin sensitivity. Notably, clinical-grade menin and EP300 inhibitors demonstrated synergistic activity against primary patients with MM samples cultured ex vivo and against the syngeneic Vk*MYC MM model in vivo. Molecular analysis revealed deep and synergistic suppression of IRF4 potentiated by the combination. Altogether, our comprehensive study identified menin as a promising target in MM and charts potential paths for rapid clinical translation.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104928"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.exphem.2025.104922
Zining Yang, Hui Cheng, Tao Cheng, Can Li, Jingxuan Li, Ruixia Sun
The developmental transition from early embryonic hematopoiesis to adult bone marrow hematopoiesis is a complex process that remains poorly understood. In particular, the cellular composition and regulatory mechanisms of the microenvironment during the initial engraftment and establishment of hematopoietic stem cells (HSCs) in the bone marrow are unclear. Understanding these niche components is essential to reveal how hematopoiesis develops and adapts.
In this study, we identify a previously unrecognized population of mature mast cells transiently present across multiple hematopoietic organs—including liver, spleen, and bone marrow—during early bone marrow hematopoiesis in both humans and mice.
These mast cells display distinct molecular markers and mature granule morphology, indicating their functional activity. Using in vitro coculture experiments, we show that mast cells directly support HSC function through the secretion of serotonin (5-HT). Depletion of mast cells during the perinatal period leads to significantly reduced 5-HT levels in the spleen and a marked decrease in hematopoietic stem and progenitor cell (HSPC) numbers. This reveals a critical role for mast cell-derived serotonin in regulating early hematopoiesis. We also provide transcriptomic profiles of mast cells from neonatal mouse hematopoietic tissues, expanding the cross-tissue transcriptomic atlas of mouse mast cells and revealing specialized gene expression signatures linked to their developmental function.
Together, these findings have revealed the new role of mast cells in supporting hematopoiesis during specific developmental windows, highlighting their significance as microenvironment regulators in the early hematopoietic development of both humans and mice.
{"title":"2009 – MAST CELLS SUPPORT HEMATOPOIETIC STEM CELL FUNCTION DURING THE TRANSITION TO BONE MARROW HEMATOPOIESIS","authors":"Zining Yang, Hui Cheng, Tao Cheng, Can Li, Jingxuan Li, Ruixia Sun","doi":"10.1016/j.exphem.2025.104922","DOIUrl":"10.1016/j.exphem.2025.104922","url":null,"abstract":"<div><div>The developmental transition from early embryonic hematopoiesis to adult bone marrow hematopoiesis is a complex process that remains poorly understood. In particular, the cellular composition and regulatory mechanisms of the microenvironment during the initial engraftment and establishment of hematopoietic stem cells (HSCs) in the bone marrow are unclear. Understanding these niche components is essential to reveal how hematopoiesis develops and adapts.</div><div>In this study, we identify a previously unrecognized population of mature mast cells transiently present across multiple hematopoietic organs—including liver, spleen, and bone marrow—during early bone marrow hematopoiesis in both humans and mice.</div><div>These mast cells display distinct molecular markers and mature granule morphology, indicating their functional activity. Using in vitro coculture experiments, we show that mast cells directly support HSC function through the secretion of serotonin (5-HT). Depletion of mast cells during the perinatal period leads to significantly reduced 5-HT levels in the spleen and a marked decrease in hematopoietic stem and progenitor cell (HSPC) numbers. This reveals a critical role for mast cell-derived serotonin in regulating early hematopoiesis. We also provide transcriptomic profiles of mast cells from neonatal mouse hematopoietic tissues, expanding the cross-tissue transcriptomic atlas of mouse mast cells and revealing specialized gene expression signatures linked to their developmental function.</div><div>Together, these findings have revealed the new role of mast cells in supporting hematopoiesis during specific developmental windows, highlighting their significance as microenvironment regulators in the early hematopoietic development of both humans and mice.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104922"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.exphem.2025.104906
Florian Perner
The mixed lineage leukemia (KMT2A/MLL1) gene is critical for hematopoiesis, but its translocation drives aggressive, treatment-resistant leukemias in infants and adults. Although previous targeted strategies showed limited efficacy, the recent development of menin inhibitors, disrupting the KMT2A-menin interaction, demonstrated significant promise. However, therapeutic resistance to these menin inhibitors emerges rapidly under monotherapy, highlighting a critical challenge and the need for deeper molecular understanding to guide intervention. A critical distinction between this class of compounds and conventional chemotherapeutic agents or apoptosis-inducing drugs like venetoclax lies in their mechanism of action. Unlike these agents, which typically trigger rapid cell death, menin inhibitors do not induce immediate cytotoxicity. Instead, they alleviate the differentiation blockade by reprogramming aberrant oncogenic chromatin states. As a result, the time to achieve the best clinical response is prolonged, with leukemia cells persisting for weeks to months in both preclinical models and early-phase clinical trials. During this extended period of persistence, leukemia cells undergo a complex adaptive process, transitioning into a drug-tolerant persister state that enables them to withstand therapeutic pressure. Interestingly, the molecular signatures of these persister cells closely resemble those observed in drug-tolerant cancer cells across other tumor types, suggesting a conserved mechanism of cellular plasticity that transcends cancer subtypes and treatment modalities. In leukemia, this adaptive state is characterized by cellular dormancy and the emergence of transcriptional and immunophenotypic features indicative of myeloid differentiation. These findings underscore a significant clinical challenge: in this context, defining the tipping point between a cell retaining leukemogenic potential and a terminally differentiated cell in diagnostic assays becomes difficult, if not impossible. This ambiguity highlights the need for more precise biomarkers to monitor therapeutic responses and predict clinical outcomes in patients treated with menin inhibitors.
{"title":"1026 – CELLULAR PLASTICITY DRIVES PERSISTENCE AND RESISTANCE OF LEUKEMIA CELLS UNDER MENIN INHIBITOR TREATMENT","authors":"Florian Perner","doi":"10.1016/j.exphem.2025.104906","DOIUrl":"10.1016/j.exphem.2025.104906","url":null,"abstract":"<div><div>The mixed lineage leukemia (KMT2A/MLL1) gene is critical for hematopoiesis, but its translocation drives aggressive, treatment-resistant leukemias in infants and adults. Although previous targeted strategies showed limited efficacy, the recent development of menin inhibitors, disrupting the KMT2A-menin interaction, demonstrated significant promise. However, therapeutic resistance to these menin inhibitors emerges rapidly under monotherapy, highlighting a critical challenge and the need for deeper molecular understanding to guide intervention. A critical distinction between this class of compounds and conventional chemotherapeutic agents or apoptosis-inducing drugs like venetoclax lies in their mechanism of action. Unlike these agents, which typically trigger rapid cell death, menin inhibitors do not induce immediate cytotoxicity. Instead, they alleviate the differentiation blockade by reprogramming aberrant oncogenic chromatin states. As a result, the time to achieve the best clinical response is prolonged, with leukemia cells persisting for weeks to months in both preclinical models and early-phase clinical trials. During this extended period of persistence, leukemia cells undergo a complex adaptive process, transitioning into a drug-tolerant persister state that enables them to withstand therapeutic pressure. Interestingly, the molecular signatures of these persister cells closely resemble those observed in drug-tolerant cancer cells across other tumor types, suggesting a conserved mechanism of cellular plasticity that transcends cancer subtypes and treatment modalities. In leukemia, this adaptive state is characterized by cellular dormancy and the emergence of transcriptional and immunophenotypic features indicative of myeloid differentiation. These findings underscore a significant clinical challenge: in this context, defining the tipping point between a cell retaining leukemogenic potential and a terminally differentiated cell in diagnostic assays becomes difficult, if not impossible. This ambiguity highlights the need for more precise biomarkers to monitor therapeutic responses and predict clinical outcomes in patients treated with menin inhibitors.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104906"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.exphem.2025.104974
Ryo Yamamoto
Self-renewal and differentiation are inherent properties of hematopoietic stem cells (HSCs) that are necessary to support hematopoiesis; however, the underlying mechanisms, especially in humans, remain unclear. Here, using the cynomolgus macaque as a surrogate model, we develop a new gating strategy to isolate with high purity transplantable cynomolgus HSCs and generate a single-cell transcriptomic map of cynomolgus HSCs and progenitor cells—covering gestational periods previously not analyzed in humans.
We performed single-cell transcriptomic analysis using 10 × genomics and Smart-seq technologies. This study presents a single-cell transcriptomic analysis of CD34hi hematopoietic stem and progenitor cells (HSPCs) from cynomolgus monkeys across developmental stages—fetal liver, fetal bone marrow, and adult bone marrow. We found that there are dynamic shifts in HSPC composition with development: HSC/MPP frequencies peak in late second trimester and decrease with age, whereas myeloid and lymphoid progenitors increase and erythroid/megakaryocyte lineages decline. Developmental and tissue-specific gene expression differences were identified in HSCs, such as higher mitochondrial activity in fetal HSCs and NF-κB–related genes in aged ABM-HSCs. Furthermore, novel surface markers for transcriptionally purified HSCs were identified, offering improved tools for future HSC isolation. We anticipate that our comprehensive data set will serve as a basis for building an HSC atlas of cynomolgus monkeys that will facilitate a better understanding of conserved and nonconserved properties as well as mechanisms between nonhuman primates (NHPs) and humans, which will be necessary for better translational applications in the future.
{"title":"3033 – ATLAS OF CYNOMOLGUS MACAQUE HEMATOPOIESIS","authors":"Ryo Yamamoto","doi":"10.1016/j.exphem.2025.104974","DOIUrl":"10.1016/j.exphem.2025.104974","url":null,"abstract":"<div><div>Self-renewal and differentiation are inherent properties of hematopoietic stem cells (HSCs) that are necessary to support hematopoiesis; however, the underlying mechanisms, especially in humans, remain unclear. Here, using the cynomolgus macaque as a surrogate model, we develop a new gating strategy to isolate with high purity transplantable cynomolgus HSCs and generate a single-cell transcriptomic map of cynomolgus HSCs and progenitor cells—covering gestational periods previously not analyzed in humans.</div><div>We performed single-cell transcriptomic analysis using 10 × genomics and Smart-seq technologies. This study presents a single-cell transcriptomic analysis of CD34hi hematopoietic stem and progenitor cells (HSPCs) from cynomolgus monkeys across developmental stages—fetal liver, fetal bone marrow, and adult bone marrow. We found that there are dynamic shifts in HSPC composition with development: HSC/MPP frequencies peak in late second trimester and decrease with age, whereas myeloid and lymphoid progenitors increase and erythroid/megakaryocyte lineages decline. Developmental and tissue-specific gene expression differences were identified in HSCs, such as higher mitochondrial activity in fetal HSCs and NF-κB–related genes in aged ABM-HSCs. Furthermore, novel surface markers for transcriptionally purified HSCs were identified, offering improved tools for future HSC isolation. We anticipate that our comprehensive data set will serve as a basis for building an HSC atlas of cynomolgus monkeys that will facilitate a better understanding of conserved and nonconserved properties as well as mechanisms between nonhuman primates (NHPs) and humans, which will be necessary for better translational applications in the future.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104974"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
During embryogenesis, hematopoietic stem cells (HSCs) arise from hemogenic endothelial cells (HECs). HECs enter endothelial-to-hematopoietic transition (EHT) and differentiate into HSCs via pre-HSCs. Previously, we reported that two cytokines and feeder cells were sufficient to induce HSCs from HECs and pre-HSCs isolated from mouse embryos at embryonic day 10.5 (E10.5). However, the signaling requirements at earlier developmental stages remain largely undefined. In this study, we sought to identify the key signaling factors required to induce HSCs from E9.5 HECs in vitro. Transcriptomic profiling of E9.5 mouse embryos detected activation of bone morphogenetic protein (BMP) signaling in HECs. BMP4 treatment in the culture system enhanced the generation of multilineage hematopoietic colonies and long-term repopulating HSCs, as confirmed using colony-forming and transplantation assays. Furthermore, early-stage HECs capable of forming HSCs expressed the BMP4 receptor. These results suggest that BMP4 plays a key role in promoting the emergence of transplantable HSCs from early HECs and provides insight into stage-specific requirements for HSC development. These findings may contribute to establishing conditions for in vitro derivation of HSCs from pluripotent stem cells.
{"title":"3034 – IN VITRO INDUCTION OF HEMATOPOIETIC STEM CELLS FROM EARLY HEMOGENIC ENDOTHELIAL CELLS","authors":"Mariko Tsuruda , Saori Morino-Koga , Xueyu Zhao , Shingo Usuki , Kei-ichiro Yasunaga , Tomomasa Yokomizo , Ryuichi Nishinakamura , Toshio Suda , Minetaro Ogawa","doi":"10.1016/j.exphem.2025.104975","DOIUrl":"10.1016/j.exphem.2025.104975","url":null,"abstract":"<div><div>During embryogenesis, hematopoietic stem cells (HSCs) arise from hemogenic endothelial cells (HECs). HECs enter endothelial-to-hematopoietic transition (EHT) and differentiate into HSCs via pre-HSCs. Previously, we reported that two cytokines and feeder cells were sufficient to induce HSCs from HECs and pre-HSCs isolated from mouse embryos at embryonic day 10.5 (E10.5). However, the signaling requirements at earlier developmental stages remain largely undefined. In this study, we sought to identify the key signaling factors required to induce HSCs from E9.5 HECs in vitro. Transcriptomic profiling of E9.5 mouse embryos detected activation of bone morphogenetic protein (BMP) signaling in HECs. BMP4 treatment in the culture system enhanced the generation of multilineage hematopoietic colonies and long-term repopulating HSCs, as confirmed using colony-forming and transplantation assays. Furthermore, early-stage HECs capable of forming HSCs expressed the BMP4 receptor. These results suggest that BMP4 plays a key role in promoting the emergence of transplantable HSCs from early HECs and provides insight into stage-specific requirements for HSC development. These findings may contribute to establishing conditions for in vitro derivation of HSCs from pluripotent stem cells.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104975"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emergence of definitive hematopoietic stem cells (HSCs) during embryonic development is underpinned by the crucial process of endothelial-to-hematopoietic transition (EHT). Therein, HSCs and progenitors are specified from a specialized subset of endothelial cells termed hemogenic endothelium (HE). These cells reside in the aorta-gonad-mesonephros (AGM) region, namely in the ventral wall of the dorsal aorta, and acquire hematopoietic potential through an incompletely characterized morphogenetic and transcriptional programming process that generates the first self-renewing, multilineage HSCs.
We made use of our previously described mouse embryonic stem cell-based 3D hemogenic gastruloid (haemGx) to dissect the dynamic specification of HE and decipher the morpho-molecular reconfiguration that underpins EHT. The haemGx model recapitulates temporally accurate emergence of CD31+CD34+Kit+ cells with HE characteristics, followed by sequential waves of CD41+ and CD45+ cells, corresponding to hematopoietic progenitors.
We integrated high-content microscopy, flow cytometry, and scRNA-seq, coupled to gene regulatory network analysis, to comprehensively capture the transcriptional dynamics of EHT and model HSCs’ emergence in silico. We further dissected intrinsic and extrinsic contributions to EHT and hematopoietic specification by establishing a novel endothelial culture system derived from haemGx and exploring endothelial and hematopoietic formation with different cellular compositions.
Our integrated approach provides a mechanistically tractable model of HE specification and EHT. Comprehensive inference of the dynamic rules underpinning the earliest events in hematopoietic specification will be pivotal to the design of high-efficiency protocols for in vitro production of HSCs.
{"title":"3035 – HEMOGENIC GASTRULOIDS CAPTURE DYNAMIC SPECIFICATION OF HE AND EHT AND INFORM RULES OF HSCS FORMATION","authors":"Ylenia Cicirò , Denise Ragusa , Ayona Johns , Camilla Cerutti , Cristina Pina","doi":"10.1016/j.exphem.2025.104976","DOIUrl":"10.1016/j.exphem.2025.104976","url":null,"abstract":"<div><div>Emergence of definitive hematopoietic stem cells (HSCs) during embryonic development is underpinned by the crucial process of endothelial-to-hematopoietic transition (EHT). Therein, HSCs and progenitors are specified from a specialized subset of endothelial cells termed hemogenic endothelium (HE). These cells reside in the aorta-gonad-mesonephros (AGM) region, namely in the ventral wall of the dorsal aorta, and acquire hematopoietic potential through an incompletely characterized morphogenetic and transcriptional programming process that generates the first self-renewing, multilineage HSCs.</div><div>We made use of our previously described mouse embryonic stem cell-based 3D hemogenic gastruloid (haemGx) to dissect the dynamic specification of HE and decipher the morpho-molecular reconfiguration that underpins EHT. The haemGx model recapitulates temporally accurate emergence of CD31+CD34+Kit+ cells with HE characteristics, followed by sequential waves of CD41+ and CD45+ cells, corresponding to hematopoietic progenitors.</div><div>We integrated high-content microscopy, flow cytometry, and scRNA-seq, coupled to gene regulatory network analysis, to comprehensively capture the transcriptional dynamics of EHT and model HSCs’ emergence in silico. We further dissected intrinsic and extrinsic contributions to EHT and hematopoietic specification by establishing a novel endothelial culture system derived from haemGx and exploring endothelial and hematopoietic formation with different cellular compositions.</div><div>Our integrated approach provides a mechanistically tractable model of HE specification and EHT. Comprehensive inference of the dynamic rules underpinning the earliest events in hematopoietic specification will be pivotal to the design of high-efficiency protocols for in vitro production of HSCs.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104976"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.exphem.2025.104977
Yumin Liu , Sifan Luo , Yuehang Chen , Zhuan Li
An understanding of the mechanisms regulating embryonic hematopoietic stem cell (HSC) development would facilitate their regeneration. The aorta gonad-mesonephros (AGM) region is the site for HSC production from hemogenic endothelial cells (HEC) through a process termed endothelial-to-hematopoietic transition (EHT). Although several regulators are involved in this process, the role of autophagy (macroautophagy) in preliver hematopoiesis remains unclear. Here, we investigated how autophagy influences the EHT in the AGM region. First, we showed that different states of autophagy existed in hematopoietic precursors and correlated with hematopoietic potential based on the RFP-EGFP-LC3 (LC3R/G) mouse model. The treatment with autophagy inhibitors resulted in the reduction of hematopoietic progenitors, indicating the possible roles of autophagy in hematopoietic development.
Furthermore, we generated Atg5 conditional knockout (cKO) mice (Vec-Cre; Atg5fl/fl) to disrupt autophagy. By combining LC3R/G with cKO embryos, we detected that the autophagic process was blocked in the hematopoietic-related cells, validating the role of Atg5 in autophagy. Atg5 deficiency impaired hematopoietic stem/progenitor cell (HSPC) function in the AGM region, expanded hematopoietic clusters, and increased immature pre-HSC I production. Trajectory analysis further demonstrated the delay of pre-HSC I maturation, collectively indicating disrupted EHT. Comparison analysis of transcriptomics between the cKO and control group showed increased interactions of Ncl-Ptn and Ncl-Mdk. Our functional and immunostaining data confirmed the altered nucleolin (NCL) distribution and the rescue role played by AS1411 (the aptamer of NCL) in the HEC and pre-HSC I fractions. In summary, we have discovered that autophagy regulates the EHT process and the maturation of pre-HSC from HEC, possibly through NCL distribution.
{"title":"3036 – AUTOPHAGY REGULATES THE MATURATION OF HEMATOPOIETIC PRECURSORS IN THE EMBRYO","authors":"Yumin Liu , Sifan Luo , Yuehang Chen , Zhuan Li","doi":"10.1016/j.exphem.2025.104977","DOIUrl":"10.1016/j.exphem.2025.104977","url":null,"abstract":"<div><div>An understanding of the mechanisms regulating embryonic hematopoietic stem cell (HSC) development would facilitate their regeneration. The aorta gonad-mesonephros (AGM) region is the site for HSC production from hemogenic endothelial cells (HEC) through a process termed endothelial-to-hematopoietic transition (EHT). Although several regulators are involved in this process, the role of autophagy (macroautophagy) in preliver hematopoiesis remains unclear. Here, we investigated how autophagy influences the EHT in the AGM region. First, we showed that different states of autophagy existed in hematopoietic precursors and correlated with hematopoietic potential based on the RFP-EGFP-LC3 (LC3R/G) mouse model. The treatment with autophagy inhibitors resulted in the reduction of hematopoietic progenitors, indicating the possible roles of autophagy in hematopoietic development.</div><div>Furthermore, we generated Atg5 conditional knockout (cKO) mice (Vec-Cre; Atg5fl/fl) to disrupt autophagy. By combining LC3R/G with cKO embryos, we detected that the autophagic process was blocked in the hematopoietic-related cells, validating the role of Atg5 in autophagy. Atg5 deficiency impaired hematopoietic stem/progenitor cell (HSPC) function in the AGM region, expanded hematopoietic clusters, and increased immature pre-HSC I production. Trajectory analysis further demonstrated the delay of pre-HSC I maturation, collectively indicating disrupted EHT. Comparison analysis of transcriptomics between the cKO and control group showed increased interactions of Ncl-Ptn and Ncl-Mdk. Our functional and immunostaining data confirmed the altered nucleolin (NCL) distribution and the rescue role played by AS1411 (the aptamer of NCL) in the HEC and pre-HSC I fractions. In summary, we have discovered that autophagy regulates the EHT process and the maturation of pre-HSC from HEC, possibly through NCL distribution.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104977"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.exphem.2025.104899
Jarrod Dudakov
The thymus, which is the primary site of T cell development, is extremely sensitive to insult but also has a remarkable capacity for endogenous repair. However, even though there is continual thymic involution and regeneration in response to everyday insults like stress and infection, profound thymic damage, such as ionizing radiation, leads to prolonged T cell lymphopenia. One approach to developing therapies to boost thymic function after radiation injury is to understand and exploit the processes underlying endogenous repair.
We have identified that the balance of cell death detection is crucial for triggering endogenous regenerative responses in the thymus. Specifically, immunologically silent apoptosis (which is abundant in thymocytes during steady-state) is suppressive to the regenerative program, but in contrast, after thymic damage, a switch toward immunogenic cell death (ICD) can promote regeneration. Importantly, many of these pathways can be therapeutically targeted to improve thymic recovery after radiation injury. However, induction of ICD (and specifically the cleavage of caspase-1) also leads to the activation of proinflammatory factors such as IL-18 and IL-1β. Although IL-1β did not seem to impact regeneration after injury, IL-18 limited repair by stimulating NK cells and their cytotoxic program, which targets thymic epithelial cells, which are crucial for supporting T cell development. Notably, this proinflammatory axis is not the only limitation to thymus repair, with aging-associated epithelial remodeling also contributing to blunted regenerative responses with age.
Together, these studies not only further defined the cellular and molecular regulators of thymic damage and repair after injury but also demonstrated the critical need for balancing proregenerative and suppressive signals in developing optimal therapies for thymus recovery and T cell reconstitution.
{"title":"1019 – DYING TO REGENERATE: ENDOGENOUS MECHANISMS OF TISSUE REPAIR IN THE THYMUS","authors":"Jarrod Dudakov","doi":"10.1016/j.exphem.2025.104899","DOIUrl":"10.1016/j.exphem.2025.104899","url":null,"abstract":"<div><div>The thymus, which is the primary site of T cell development, is extremely sensitive to insult but also has a remarkable capacity for endogenous repair. However, even though there is continual thymic involution and regeneration in response to everyday insults like stress and infection, profound thymic damage, such as ionizing radiation, leads to prolonged T cell lymphopenia. One approach to developing therapies to boost thymic function after radiation injury is to understand and exploit the processes underlying endogenous repair.</div><div>We have identified that the balance of cell death detection is crucial for triggering endogenous regenerative responses in the thymus. Specifically, immunologically silent apoptosis (which is abundant in thymocytes during steady-state) is suppressive to the regenerative program, but in contrast, after thymic damage, a switch toward immunogenic cell death (ICD) can promote regeneration. Importantly, many of these pathways can be therapeutically targeted to improve thymic recovery after radiation injury. However, induction of ICD (and specifically the cleavage of caspase-1) also leads to the activation of proinflammatory factors such as IL-18 and IL-1β. Although IL-1β did not seem to impact regeneration after injury, IL-18 limited repair by stimulating NK cells and their cytotoxic program, which targets thymic epithelial cells, which are crucial for supporting T cell development. Notably, this proinflammatory axis is not the only limitation to thymus repair, with aging-associated epithelial remodeling also contributing to blunted regenerative responses with age.</div><div>Together, these studies not only further defined the cellular and molecular regulators of thymic damage and repair after injury but also demonstrated the critical need for balancing proregenerative and suppressive signals in developing optimal therapies for thymus recovery and T cell reconstitution.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"151 ","pages":"Article 104899"},"PeriodicalIF":2.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}